Table 1 Proportion of patients with KRAS, BRAF, and MEK1/2 mutations in our study and a review of the literature

	Niihori et al,13 Narumi et al25	Rodriguez-Viciana et al14	Schubbert et al15		Carta et al16		Rauen et al29	Zenker et al21			This study
	CFC	CFC	CFC	NS PTPN11	CFC	NS PTPN11	CS HRAS-	CFC	CS HRAS	NS PTPN11	CFC	CS HRAS-	NS PTPN11
Patients, n	56	23	12	175	8	87	3	21	3	236	40	20	70
KRAS, n (%)	3 (5.5)	—	1 (8.3)	5 (3)	0	2 (2.3)	—	2 +1CFC/NS (14.3)	2 (66.7)	7 (3)	1 (2.5)	2 (10)	4 (5.7)
BRAF, n (%)	24 (43)	18 (78)	—	—	—	—	2 (66.7)	—	—	—	14 (35)	8 (40)	0
MEK1, n (%)	4 (7)	2 (9)	—	—	—	—	—	—	—	—	4 (10)	4 (20)	3 (4.3)
MEK2, n (%)	4 (7)	1 (4.3)	—	—	—	—	—	—	—	—	4 (10)	0	0
Patients with a mutation, n (%)	35 (62.5)	21 (91.3)	1 (8.3)	5 (3)	0	2 (2.3)	2 (66.7)	3 (14.3)	2 (66.7)	7 (3)	23 (57.5)	14 (70)	7 (10)

CFC, cardio-facio-cutaneous syndrome; CS, Costello syndrome; NS, Noonan syndrome.